<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04369755</url>
  </required_header>
  <id_info>
    <org_study_id>2019-A02689-48</org_study_id>
    <nct_id>NCT04369755</nct_id>
  </id_info>
  <brief_title>MR7T-Healthy-PTX : Brain Exploration in Magnetic Resonance Imaging in Parallel Transmission Mode (pTX) at 7 Tesla</brief_title>
  <official_title>Pilote Study : Brain Exploration in Magnetic Resonance Imaging in Parallel Transmission Mode (pTX) at 7 Tesla on Healthy Subject at Poitiers University Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Magnetic resonance imaging (MRI) is a non-invasive imaging modality used in routine clinical&#xD;
      practice for clinical diagnosis by visualizing the anatomical structure and in vivo function&#xD;
      of certain organs. The development of ultra-high field MRI systems with 7.0-T or higher,&#xD;
      gives access to a new field of exploration of the human body by improving the speed of&#xD;
      acquisition but also a better signal-to-noise ratio (SNR) and better resolution. In order to&#xD;
      fully exploit the potential of these ultra-high field MRI scanners, various technical issues&#xD;
      must be adressed. Indeed, the non-uniformity of the transmission field is one of them leading&#xD;
      to non-uniform images with spatially varying contrast. Thus the pTX (parallel transmission)&#xD;
      mode using multiple transmission channels allows spatial and temporal control over the RF&#xD;
      waves.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 25, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the improvement of the Signal to Noise Ratio (SNR) in parallel transmission mode (pTx) versus without pTx at 7.0 T on different cerebral anatomical regions/structures (central gray nuclei, cerebellum, white matter, cortex).</measure>
    <time_frame>1 year</time_frame>
    <description>The main evaluation criterion is the value of the signal-to-noise ratio in a global way but also by a unit comparison approach (voxel to voxel).&#xD;
It will be a question of linking these variations to the flip angles but also to the probable inhomogeneities of the B1+ field.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the body temperature</measure>
    <time_frame>1 year</time_frame>
    <description>Measurement of body temperature in healthy volunteers using a forehead thermometer before and after examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of anxiety before, during and after the MRI</measure>
    <time_frame>1 year</time_frame>
    <description>Measurement of the healthy subject's feelings about the exam (anxiety, heat, nausea) using a grid proposed at the end of the exam.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>MRI</condition>
  <condition>PTX</condition>
  <condition>BRAIN</condition>
  <condition>7 TESLA</condition>
  <arm_group>
    <arm_group_label>MRI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A MRI on PTX mode will be done on healthy subjects (approx. 90 min of sequences)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MRI</intervention_name>
    <description>A MRI in PTX mode will be done on healthy subject (approx. 90 min of sequences)</description>
    <arm_group_label>MRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years old&#xD;
&#xD;
          -  Subject with no MRI contraindications (metallic shine, pacemaker)&#xD;
&#xD;
          -  Free subject, without guardianship or curatorship or subordination&#xD;
&#xD;
          -  A person affiliated to or beneficiary of a social security scheme.&#xD;
&#xD;
          -  Informed and signed consent by the healthy volunteer after clear and fair information&#xD;
             about the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject with a contraindication to MRI (pregnancy, ocular metallic foreign body&#xD;
             (accidental or other shrapnel); pacemaker (cardiac stimulator), implantable&#xD;
             defibrillator, non MRI 7.0 T compatible neurostimulator, cochlear implants and&#xD;
             generally any irremovably implanted electronic medical device; metallic heart valve,&#xD;
             vascular clips formerly implanted on cranial aneurysm), metallic prostheses.&#xD;
&#xD;
          -  Healthy volunteers suffering from claustrophobia&#xD;
&#xD;
          -  Persons not benefiting from a Social Security scheme or not benefiting from it through&#xD;
             a third party.&#xD;
&#xD;
          -  Persons benefiting from reinforced protection, i.e. minors, pregnant and breastfeeding&#xD;
             women, persons deprived of their liberty by a judicial or administrative decision,&#xD;
             persons staying in a health or social institution, adults under legal protection and&#xD;
             finally, patients in emergency situations.&#xD;
&#xD;
          -  Pregnant or breastfeeding women, women of childbearing age who do not have effective&#xD;
             contraception (hormonal/mechanical: per os, injectable, transcutaneous, implantable,&#xD;
             intrauterine device, or surgical: tubal ligation, hysterectomy, total oophorectomy).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rémy GUILLEVIN, Pr</last_name>
    <phone>05.49.44.17.91</phone>
    <email>remy.guillevin@chu-poitiers.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rémy GUILLEVIN</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 27, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2020</study_first_posted>
  <last_update_submitted>September 22, 2020</last_update_submitted>
  <last_update_submitted_qc>September 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MRI</keyword>
  <keyword>PTX</keyword>
  <keyword>BRAIN</keyword>
  <keyword>7 TESLA</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

